Blood Product Supply

Part of paid clinical trials in Dallas, Texas.

Sponsor
Methodist Health System
Study ID
NCT07490314
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Document delays and frequencies of inadequate blood products for emergent cases — OTHER
    The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals

Study Details

Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.

Key Dates

Start date
Mar 1, 2020
Status verified
Feb 2026
Primary completion
Mar 21, 2021
Completion
Jun 25, 2025

Study Design

Enrollment
100 participants (actual)

Arms

  • Arm: future policies on use of blood products from COVID-19-positive donors
    Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics.

Primary Outcome Measure

Time frame [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Methodist Dallas Medical Center- Clinical Research InstituteDallasTexas75203-

Find similar trials in Dallas, TX

By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Methodist Dallas Medical Center- Clinical Research Institute· Dallas, TX

Related Studies